US Patent 6902744 Exendin agonist formulations and methods of administration thereof
Patent 6902744 was granted and assigned to Amylin Pharmaceuticals on June, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 2 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 24 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 Oct, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+334 characters)
Article
Patent abstract
Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Andrew A. Young0
Orville G. Kolterman0
Date of Patent
June 7, 2005
0Patent Application Number
098893300
Date Filed
January 14, 2000
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6902744 Exendin agonist formulations and methods of administration thereof
Find more entities like US Patent 6902744 Exendin agonist formulations and methods of administration thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.